Milestone Pharmaceuticals Stock Analysis
| MIST Stock | USD 1.83 0.00 0.00% |
IPO Date 9th of May 2019 | 200 Day MA 1.8524 | 50 Day MA 2.1789 | Beta 0.463 |
Milestone Pharmaceuticals holds a debt-to-equity ratio of 0.006. At this time, Milestone Pharmaceuticals' Debt Ratio is comparatively stable compared to the past year. Milestone Pharmaceuticals' financial risk is the risk to Milestone Pharmaceuticals stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Milestone Pharmaceuticals' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Milestone Pharmaceuticals' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Milestone Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Milestone Pharmaceuticals' stakeholders.
For many companies, including Milestone Pharmaceuticals, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Milestone Pharmaceuticals, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Milestone Pharmaceuticals' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 7.3117 | Enterprise Value Ebitda (1.43) | Price Sales 77.3204 | Shares Float 77 M | Wall Street Target Price 6.6 |
Milestone Pharmaceuticals is undervalued with Real Value of 3.0 and Target Price of 6.6. The main objective of Milestone Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Milestone Pharmaceuticals is worth, separate from its market price. There are two main types of Milestone Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Milestone Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Milestone Pharmaceuticals is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day ( substitute day ), Independence Day. Milestone Stock trading window is adjusted to America/New York timezone.
Milestone | Build AI portfolio with Milestone Stock |
Milestone Stock Analysis Notes
About 51.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.79. Milestone Pharmaceuticals had not issued any dividends in recent years. The entity had 1-1 split on the 24th of March 2020. Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company was incorporated in 2003 and is headquartered in Montral, Canada. Milestone Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 29 people. To find out more about Milestone Pharmaceuticals contact Joseph MBA at 514 336 0444 or learn more at https://www.milestonepharma.com.Milestone Pharmaceuticals Investment Alerts
| Milestone Pharmaceuticals may become a speculative penny stock | |
| Milestone Pharmaceuticals had very high historical volatility over the last 90 days | |
| Milestone Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (41.52 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Milestone Pharmaceuticals currently holds about 86.24 M in cash with (28.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Milestone Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635 |
Milestone Largest EPS Surprises
Earnings surprises can significantly impact Milestone Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-11 | 2024-09-30 | -0.16 | -0.1426 | 0.0174 | 10 | ||
2025-08-12 | 2025-06-30 | -0.18 | -0.2 | -0.02 | 11 | ||
2025-11-12 | 2025-09-30 | -0.16 | -0.12 | 0.04 | 25 |
Milestone Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Valeo Financial Advisors, Llc | 2025-06-30 | 130.7 K | Goldman Sachs Group Inc | 2025-06-30 | 119.4 K | Cascades Capital Asset Management, Llc | 2025-06-30 | 67.1 K | Susquehanna International Group, Llp | 2025-06-30 | 63.4 K | Northern Trust Corp | 2025-06-30 | 53 K | The Colony Group Llc | 2025-06-30 | 36 K | Royal Bank Of Canada | 2025-06-30 | 35.6 K | Jane Street Group Llc | 2025-06-30 | 31.9 K | Group One Trading, Lp | 2025-06-30 | 31.6 K | Rtw Investments, Llc | 2025-06-30 | 2.5 M | Propel Bio Management Llc | 2025-06-30 | 1.8 M |
Milestone Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 149.9 M.Milestone Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.63) | (0.66) | |
| Return On Capital Employed | (0.72) | (0.75) | |
| Return On Assets | (0.63) | (0.66) | |
| Return On Equity | (3.63) | (3.45) |
Management Efficiency
Milestone Pharmaceuticals has return on total asset (ROA) of (0.4197) % which means that it has lost $0.4197 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.6065) %, meaning that it created substantial loss on money invested by shareholders. Milestone Pharmaceuticals' management efficiency ratios could be used to measure how well Milestone Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.66 in 2026. Return On Capital Employed is likely to drop to -0.75 in 2026. At this time, Milestone Pharmaceuticals' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Other is likely to gain to about 468 K in 2026, whereas Total Current Liabilities is likely to drop slightly above 6.7 M in 2026.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.19 | 0.18 | |
| Tangible Book Value Per Share | 0.19 | 0.18 | |
| Enterprise Value Over EBITDA | (4.19) | (4.40) | |
| Price Book Value Ratio | 10.05 | 10.55 | |
| Enterprise Value Multiple | (4.19) | (4.40) | |
| Price Fair Value | 10.05 | 10.55 | |
| Enterprise Value | 202.7 M | 206 M |
Leadership at Milestone Pharmaceuticals emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Technical Drivers
As of the 9th of February, Milestone Pharmaceuticals secures the Risk Adjusted Performance of 0.0139, mean deviation of 3.24, and Downside Deviation of 4.66. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Milestone Pharmaceuticals, as well as the relationship between them.Milestone Pharmaceuticals Price Movement Analysis
Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Weighted Moving Average calculates a weight for each value in Milestone Pharmaceuticals price series with the more recent values given greater weights.
Milestone Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Milestone Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Milestone Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Milestone Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Milestone Pharmaceuticals Outstanding Bonds
Milestone Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Milestone Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Milestone bonds can be classified according to their maturity, which is the date when Milestone Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Milestone Pharmaceuticals Predictive Daily Indicators
Milestone Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Milestone Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 55450.0 | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 1.8 | |||
| Day Typical Price | 1.81 | |||
| Price Action Indicator | 0.03 |
Milestone Pharmaceuticals Forecast Models
Milestone Pharmaceuticals' time-series forecasting models are one of many Milestone Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Milestone Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Milestone Pharmaceuticals Bond Ratings
Milestone Pharmaceuticals financial ratings play a critical role in determining how much Milestone Pharmaceuticals have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Milestone Pharmaceuticals' borrowing costs.| Piotroski F Score | 3 | Frail | View |
| Beneish M Score | (5.09) | Unlikely Manipulator | View |
Milestone Pharmaceuticals Debt to Cash Allocation
Milestone Pharmaceuticals currently holds 54.8 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Milestone Pharmaceuticals has a current ratio of 20.83, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Milestone Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.Milestone Pharmaceuticals Total Assets Over Time
Milestone Pharmaceuticals Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Milestone Pharmaceuticals uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Milestone Pharmaceuticals Debt Ratio | 69.0 |
Milestone Pharmaceuticals Corporate Bonds Issued
Milestone Net Debt
Net Debt |
|
About Milestone Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Milestone Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Milestone shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Milestone Pharmaceuticals. By using and applying Milestone Stock analysis, traders can create a robust methodology for identifying Milestone entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (68.64) | (65.21) | |
| Operating Profit Margin | (70.26) | (66.75) | |
| Net Loss | (68.64) | (65.21) |
Current Milestone Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Milestone analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Milestone analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Consensus | # of Analysts | |
| 6.6 | Buy | 4 | Odds |
Most Milestone analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Milestone stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Milestone Pharmaceuticals, talking to its executives and customers, or listening to Milestone conference calls.
Milestone Stock Analysis Indicators
Milestone Pharmaceuticals stock analysis indicators help investors evaluate how Milestone Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Milestone Pharmaceuticals shares will generate the highest return on investment. By understating and applying Milestone Pharmaceuticals stock analysis, traders can identify Milestone Pharmaceuticals position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 13.8 M | |
| Long Term Debt | 53.4 M | |
| Common Stock Shares Outstanding | 62.2 M | |
| Total Stockholder Equity | 13.1 M | |
| Total Cashflows From Investing Activities | 8.3 M | |
| Property Plant And Equipment Net | 1.6 M | |
| Cash And Short Term Investments | 69.7 M | |
| Cash | 25.3 M | |
| Accounts Payable | 1.9 M | |
| Net Debt | 29.5 M | |
| 50 Day M A | 2.1789 | |
| Total Current Liabilities | 8.1 M | |
| Other Operating Expenses | 42.1 M | |
| Non Current Assets Total | 1.6 M | |
| Stock Based Compensation | 5.8 M |
Additional Tools for Milestone Stock Analysis
When running Milestone Pharmaceuticals' price analysis, check to measure Milestone Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Milestone Pharmaceuticals is operating at the current time. Most of Milestone Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Milestone Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Milestone Pharmaceuticals' price. Additionally, you may evaluate how the addition of Milestone Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.